Seelos receives fda may proceed notice for trial of aml treatment

Seelos therapeutics receives fda may proceed notice to initiate a phase iib/iii trial of sls-005 in amyotrophic lateral sclerosis.seelos therapeutics - phase iib/iii trial plans to enroll 160 patients with either familial or sporadic als in double-blind placebo-controlled trial.

SEEL Ratings Summary

SEEL Quant Ranking